About 300 reports

  • 3.1 Overview
  • 6.7.3 MARKET SIZE

A prime example of this is the emergence of immunotherapies and PD-##/ PD-L## targeted agents.

  • Chemotherapy
  • Market Size
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Merck & Co., Inc.
  • SALES FORECAST BY CLASS FOR PROSTATE CANCER IN THE US IN 2018 AND 2028
  • GLOBAL SALES FORECAST BY COUNTRY FOR PROSTATE CANCER IN 2018 AND 2028

ONE OF ITS MOST SUCCESSFUL DRUGS TO DATE IS THE BLOCKBUSTER ANTI-PD-## IMMUNOTHERAPY KEYTRUDA.

  • Chemotherapy
  • East Asia
  • United States
  • Forecast
  • Pfizer Inc.
  • SALES FORECAST BY CLASS FOR PROSTATE CANCER IN JAPAN IN 2016 AND 2026
  • SALES FORECAST BY CLASS FOR PROSTATE CANCER IN THE US IN 2016 AND 2026

CURRENTLY ONLY ONE IMMUNOTHERAPY HAS BEEN APPROVED FOR USE IN MCRPC, THE CANCER VACCINE PROVENGE.

  • Chemotherapy
  • Hospital
  • United States
  • Forecast
  • PROVENGE group
  • Retinoids Major Producer and Their Market Share
  • DEMAND

The auto exports exceeded over ## million each year.

  • Chemotherapy
  • China
  • Demand
  • Bayer Schering Pharmaceutical Co., Ltd
  • Changchun ChangSheng Gene Pharmaceutical Co., Ltd.
  • Skin Cancer Treatment Drugs Sales Volume and Market Share by Drugs Classification in 2018 (Million Yuan/percent)
  • Skin Cancer Treatment Drugs Sales Volume (million

Immunotherapy Drugs Sales Volume α-Interferon Sales Volume ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## Zhejiang Beisheng Medicine Industry Hansheng Pharmaceutical Co., Ltd.

  • Chemotherapy
  • China
  • Demand
  • Bayer Schering Pharmaceutical Co., Ltd
  • Changchun ChangSheng Gene Pharmaceutical Co., Ltd.
  • CHEMOTHERAPY

Interferon alfa, one of the initial treatments for Kaposi sarcoma, is an example of immunotherapy.

  • Chemotherapy
  • Forecast
  • Bristol-Myers Squibb Company
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Steroids Major Producer and Their Market Share
  • DEMAND

The auto exports exceeded over ## million each year.

  • Chemotherapy
  • China
  • Demand
  • AstraZeneca China Inc.
  • Bayer Schering Pharmaceutical Co., Ltd
  • Kidney Cancer Treatment Drugs Sales Volume by Drugs Classification in 2018(percent)
  • Chapter IV

Chapter IV KIDNEY CANCER TREATMENT DRUGS PRODUCTION AND DEMAND Chart ##: Immunotherapy Drugs Sales Volume (million Yuan) The Immunotherapy Drugs contains two different kinds, and they are cytokines and cancer vaccines.

  • Chemotherapy
  • China
  • Demand
  • AstraZeneca China Inc.
  • Bayer Schering Pharmaceutical Co., Ltd
  • CRC THERAPEUTICS MARKET, GLOBAL, ALL PIPELINE PRODUCTS, PHASE II, 2018
  • 3 Marketed Products

Nivolumab as Programmed Death-## (PD-##) Inhibitor for Targeted Immunotherapy in Tumor.

  • Chemotherapy
  • Colorectal Cancer
  • Therapy
  • Market Size
  • Merck & Co., Inc.
  • SALES FOR CRC IN THE 5EU, BY DRUG CLASS, 2015-2025
  • SALES FOR CRC IN THE US, BY DRUG CLASS, 2015-2025

US KEY OPINION LEADER CURRENTLY, THERE IS ONLY ONE LATE-STAGE IMMUNOTHERAPY IN THE PIPELINE THAT TARGETS MSS PATIENTS, ROCHE' S TECENTRIQ.

  • Chemotherapy
  • Eli Lilly & Co.
  • Merck & Co., Inc.
  • Roche Group
  • Taiho Pharmaceutical Co., Ltd.
  • COMMON TREATMENT MODALITIES FOR CANCER
  • SWOT ANALYSIS CHEMOTHERAPY DRUGS MARKET

Powerful suppliers ##.

  • Chemotherapy
  • World
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Eli Lilly & Co.

Strength: ## Low; ## High F.

  • Chemotherapy
  • Bristol-Myers Squibb Company
  • Eli Lilly & Co.
  • Merck & Co., Inc.
  • Pfizer Inc.
  • LISTS THE PIPELINE DRUGS IN LATE-STAGE CLINICAL DEVELOPMENT FOR HNSCC.
  • SALES FOR HNC PRODUCTS BY DRUG CLASS, 2016-2026

THE MOST COMMON CTL TOXICITIES WERE GRADE ## AND ## FATIGUE AS WELL ASGRADE ## MYALGIA DURING THE CTL IMMUNOTHERAPY PHASE.

  • Chemotherapy
  • Japan
  • United States
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Market size and forecast

The benefits associated with immunotherapies drive the market.

  • Chemotherapy
  • World
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Pfizer Inc.
  • 4.3.6 TECENTRIQ (ATEZOLIZUMAB) - ROCHE

Nanda on Immunotherapy in Metastatic TNBC.

  • Cancer
  • Chemotherapy
  • AstraZeneca PLC
  • Novartis AG
  • Roche Group
  • OVERVIEW OF THE CLINICAL DEVELOPMENT PIPELINE IN AML
  • AMNOLAKE (TAMIBAROTENE)

CANCER IMMUNOLOGY, IMMUNOTHERAPY; ##(##): ##-##.

  • Chemotherapy
  • Astellas Pharma Inc.
  • Astex Pharmaceuticals, Inc.
  • Celgene Corporation
  • Novartis AG
  • Overview of the Development Pipeline in PDAC
  • BMS-986016

PEGVORHYALURONIDASE ALFA HAS ALREADY BEEN, AND IS CURRENTLY BEING, STUDIED IN COMBINATION WITH IMMUNOTHERAPY AGENTS SUCH AS ANTI-PD-## OR PD-L## CHECKPOINT INHIBITORS.

  • Chemotherapy
  • AbbVie Inc.
  • AstraZeneca PLC
  • Halozyme Therapeutics, Inc.
  • Merck & Co., Inc.

Immunotherapy with BCG prevents recurrence in up to of cases of superficial bladder cancer.

  • Chemotherapy
  • China
  • Demand
  • Market Size
  • Trade
  • 7.3.2 ABRAXANE (NAB-PACLITAXEL)

Randomized phase II/ III trial of active immunotherapy with OPT-##/ OPT- ## in patients with metastatic breast cancer.

  • Chemotherapy
  • Company
  • Novartis AG
  • Pfizer Inc.
  • Roche Group

The company was founded in the year 1976 and employees an over one-thousand people.

  • Chemotherapy
  • Eisai Co., Ltd.
  • Helsinn Group
  • Holding Co LLC
  • Kirin Group

Immunotherapy with BCG prevents recurrence in up to of cases of superficial bladder cancer.

  • Chemotherapy
  • China
  • Demand
  • Trade
  • Sanofi-Synthelabo Inc.

Approximately what one-year progression-free survival benefit would a PD-##/ PD-L## inhibitor + CTLA-## inhibitor combination have to demonstrate in first-line NSCLC to drive moderate-to-significant uptake?

  • Antimalarials
  • Chemotherapy
  • Lung Cancer
  • Therapy
  • United States
  • 10.1 GLOBAL MARKETS
  • NSCLC - Global Drivers and Barriers, 2015-2025

IN SEPTEMBER 2014, ITS FLAGSHIP IMMUNOTHERAPY ASSET, KEYTRUDA, WAS APPROVED IN THE US FOR MELANOMA TREATMENT, BECOMING THE FIRST ANTI-PD-## IMMUNOTHERAPY TO LAND ON THE WORLD' S LARGEST PHARMACEUTICAL MARKET.

  • Chemotherapy
  • Eli Lilly & Co.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.

Cancer can be treated by surgery, chemotherapy, radiation therapy, hormonal therapy, and targeted therapy (including immunotherapy such as monoclonal antibody therapy).

  • Chemotherapy
  • China
  • Demand
  • Forecast
  • Market Size

In melanoma models, HSP## inhibition by ganetespib increased the expression levels of interferon response genes, notably interferon-induced protein with tetratricopeptide repeats ## (IFIT##), IFIT##, and IFIT##, which was found to further enhance the T-cell-mediated killing of melanoma cells an

  • Chemotherapy
  • Lung Cancer
  • Therapy
  • United States
  • Merck & Co., Inc.

Chapter IV LIVER CANCER TREATMENT DRUGS PRODUCTION & DEMAND Other Immunomodulator BCG also finds use for immunotherapy of colorectal cancer and liver cancer.

  • Chemotherapy
  • China
  • Demand
  • Trade
  • Hainan Haiyao Company Limited

Chapter IV LIVER CANCER TREATMENT DRUGS PRODUCTION & DEMAND Other Immunomodulator BCG also finds use for immunotherapy of colorectal cancer and liver cancer.

  • Chemotherapy
  • China
  • Demand
  • Novartis AG
  • Sanofi-Synthelabo Inc.
  • Sales for Bladder Cancer by Drug Class in Japan, 2015 and 2025
  • Sales for Bladder Cancer by Drug Class in the 5EU, 2015 and 2025

IMMUNOTHERAPY ASTRAZENECA IMMUNOTHERAPY MERCK & CO.

  • Chemotherapy
  • United States
  • Demand
  • Merck & Co., Inc.
  • OncoGenex Pharmaceuticals, Inc.
  • UROLOGIC ONCOLOGY THERAPEUTICS MARKET, GLOBAL, CLINICAL PROGRAM SIZE BY STAGE OF DEVELOPMENT AND MOLECULAR TARGET (PARTICIPANTS), 2006-2016
  • UROLOGIC ONCOLOGY THERAPEUTICS MARKET, GLOBAL, CLINICAL TRIAL ATTRITION RATES BY STAGE OF DEVELOPMENT AND MOLECULAR TARGET (%), 2006-2016

Journal of Immunotherapies Cancer; ##: ##.

  • Chemotherapy
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Johnson & Johnson
  • Pfizer Inc.
  • KOL INSIGHT ON THE UPDATES TO THE BLADDER CANCER COMPETITIVE LANDSCAPE (APRIL 2017-FEBRUARY 2018)

How do you know you' re achieving a response to immunotherapy, rather than just a sustained effect from the last chemo?

  • Chemotherapy
  • United States
  • Eli Lilly & Co.
  • Merck & Co., Inc.
  • Roche Group